Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2013 09:00 ET | Source: biOasis Technologies Inc.

CEO Letter to Shareholders

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 18, 2013) - biOasis Technologies Inc., (TSX VENTURE:BTI) an industry-leading provider of technology to potentially deal with the unmet...
April 09, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis's Update on the BT2111-Herceptin(R) Program

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 9, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today an update on the advancement of its anti-cancer product candidate...
February 13, 2013 14:00 ET | Source: biOasis Technologies Inc.

biOasis Named to 2013 TSX Venture 50(R)

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 13, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces it has been named one of the 2013 TSX Venture 50® companies. The...
February 07, 2013 09:00 ET | Source: biOasis Technologies Inc.

biOasis Announces Positive Anti-Tumour Efficacy Data

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 7, 2013) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that its Transcend-Herceptin® Conjugate (BT2111) product...
December 14, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Technologies Year in Review 2012

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 14, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) today is pleased to provide a 2012 year in review. biOasis has come a long way in...
December 03, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Enters Into a Research Collaboration Agreement with UCB

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 3, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that it has entered into a research collaboration agreement with...
November 14, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Enters Into a Research & Evaluation Agreement with MedImmune

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 14, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that it has entered into a research and evaluation agreement with...
September 24, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Receives Preliminary Histopathology (Tissue Toxicity) Results on Its Herceptin(R) BT2111 Program

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 24, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces today positive results of a preliminary toxicity evaluation of test...
September 05, 2012 09:30 ET | Source: biOasis Technologies Inc.

biOasis's Herceptin(R)-BT2111 Stops Human Breast Cancer Tumor Growth in Animals

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 5, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that a key animal study in its BT2111 oncology program, showed that...
August 28, 2012 19:36 ET | Source: biOasis Technologies Inc.

biOasis Technologies Inc.: 2012-2013 Board of Directors Election, Officers Appointment and Option Grant

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 28, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces its board of directors elected by the shareholders at its Annual General...